Genlantis Diagnostics Inc. – Trademark Portfolio
Entity Type: 03
Genlantis Diagnostics Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 2 are pending. Notable registered marks include MYQUIK, TRIQUIK, and GENLANTIS. The owner is based in San Diego, CA.
8447 Miramar Mall
San Diego, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
Genlantis Diagnostics Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Genlantis Diagnostics Inc. have?
Genlantis Diagnostics Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 pending.
What trademark classes does Genlantis Diagnostics Inc. file in?
Genlantis Diagnostics Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Genlantis Diagnostics Inc.'s most well-known trademarks?
Genlantis Diagnostics Inc.'s registered trademark portfolio includes well-known marks such as MYQUIK, TRIQUIK, and GENLANTIS. These are among 3 currently registered trademarks in the portfolio.
What is Genlantis Diagnostics Inc.'s trademark registration success rate?
Genlantis Diagnostics Inc. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 2 applications are pending review.